glp 1 weight loss after stopping How GLP-1 medications work and their limitations When you stop GLP-1 medications,

The companys oral GLP-1 is on track for obesity approval and launch in 2026

GLP-1 agonists primarily cause gastrointestinal effectsnausea, vomiting, constipation, or diarrheathat typically subside within weeks as the body adjusts

Accordingly, the diabetes drug market is expected to balloon from $29.81 billion in 2021 to $61.6 billion by 2030

In this Straight Talk video, our Healthcare Economist Mike Bertaut explores whether Louisiana Blue will cover GLP-1s to treat obesity in people without diabetes

As prescription drugs, they carry potential risks like gastrointestinal upset, pancreatitis, and gallbladder issues, so comprehensive health checks and professional evaluation are essential before starting, with regular follow-ups to monitor key indicators during use